» Articles » PMID: 39081641

Heart Failure With Preserved Ejection Fraction and Frailty: From Young to Superaged Coexisting HFpEF and Frailty

Overview
Date 2024 Jul 31
PMID 39081641
Authors
Affiliations
Soon will be listed here.
Abstract

Being commonly diagnosed in elderly women and associated with comorbidities as well as ageing-related cardio-vascular changes, heart failure with preserved ejection fraction (HFpEF) has been recently considered as a distinct cardiogeriatric syndrome. Frailty is another frequent geriatric syndrome. HFpEF and frailty share common underlying mechanisms, often co-exist, and represent each other's risk factors. A threshold of 65 years old is usually used to screen patients for both frailty and HFpEF in research and clinical settings. However, both HFpEF and frailty are very heterogenous conditions that may develop at younger ages. In this review we aim to provide a broader overview on the coexistence of HFpEF and frailty throughout the lifetime. We hypothesize that HFpEF and frailty patients' profiles (young, elderly, superaged) represent a continuum of the common ageing process modified by cumulative exposure to risk factors resulting to a presentation of HFpEF and frailty at different ages. We believe, that suggested approach might stimulate assessment of frailty in HFpEF assessment and vice versa regardless of age and early implementation of targeted interventions. Future studies of pathophysiology, clinical features, and outcomes of frailty in HFpEF by age are needed.

References
1.
Rockwood K, Stadnyk K, Macknight C, McDowell I, Hebert R, Hogan D . A brief clinical instrument to classify frailty in elderly people. Lancet. 1999; 353(9148):205-6. DOI: 10.1016/S0140-6736(98)04402-X. View

2.
Joosten L, van Doorn S, van de Ven P, Kohlen B, Nierman M, Koek H . Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial. Circulation. 2023; 149(4):279-289. DOI: 10.1161/CIRCULATIONAHA.123.066485. View

3.
Pfeffer M, Shah A, Borlaug B . Heart Failure With Preserved Ejection Fraction In Perspective. Circ Res. 2019; 124(11):1598-1617. PMC: 6534165. DOI: 10.1161/CIRCRESAHA.119.313572. View

4.
Zhao L, Zierath R, John J, Claggett B, Hall M, Clark 3rd D . Subclinical Risk Factors for Heart Failure With Preserved and Reduced Ejection Fraction Among Black Adults. JAMA Netw Open. 2022; 5(9):e2231878. PMC: 9478780. DOI: 10.1001/jamanetworkopen.2022.31878. View

5.
Anker S, Usman M, Anker M, Butler J, Bohm M, Abraham W . Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology,.... Eur J Heart Fail. 2023; 25(7):936-955. DOI: 10.1002/ejhf.2894. View